We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc. (“PRNB” or the “Company”) (NASDAQ: PRNB) in connection with the proposed acquisition of the Company by French pharmaceutical company, Sanofi.  Under the terms of the acquisition agreement, which is structured like a tender offer, PRNB shareholders will receive $100.00 in cash for each share of PRNB common stock that they own.

‍WeissLaw is investigating whether PRNB’s board acted to maximize shareholder value in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of the proposed acquisition of the Company, and whether all information regarding the valuation of the deal will be fully and fairly disclosed to PRNB shareholders.  Notably, at least one analyst set a target price of $130.00 per PRNB share.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com